ALLMedicine™ Hyperkalemia Center

Oct 18th, 2020 - Available information about prognostic implications of potassium levels alteration in the setting of acute heart failure (AHF) is scarce. We aim to describe the prevalence of dyskalemia (hypo or hyperkalemia), its dynamic changes during AHF-hospit...

Oct 18th, 2020 - The immune checkpoint inhibitors (ICPi) revolutionize the cancer therapeutics, though not being devoid of toxicity. The immune-related primary adrenal insufficiency (PAI) is a rare, yet potentially life-threatening, adverse event, posing diagnosti...

Oct 7th, 2020 - Mineralocorticoid receptor antagonists (MRA) can reduce cardiovascular morbidity and mortality in patients with heart failure and ischemic heart disease. In addition, these agents have been used in patients with diabetic nephropathy to control pro...

Oct 2nd, 2020 - Hyperkalemia (HK) is a serious medical condition that can cause potentially fatal cardiac arrhythmias. Patients with heart failure (HF) are at risk of HK due to underlying chronic kidney disease and use of guideline-recommended renin-angiotensin-a...

Sep 30th, 2020 - Tumor lysis syndrome (TLS) is an oncologic emergency due to a rapid break down of malignant cells usually induced by cytotoxic therapy, with hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and serious clinical consequences such as ac...

Oct 18th, 2020 - Available information about prognostic implications of potassium levels alteration in the setting of acute heart failure (AHF) is scarce. We aim to describe the prevalence of dyskalemia (hypo or hyperkalemia), its dynamic changes during AHF-hospit...

Oct 18th, 2020 - The immune checkpoint inhibitors (ICPi) revolutionize the cancer therapeutics, though not being devoid of toxicity. The immune-related primary adrenal insufficiency (PAI) is a rare, yet potentially life-threatening, adverse event, posing diagnosti...

Oct 7th, 2020 - Mineralocorticoid receptor antagonists (MRA) can reduce cardiovascular morbidity and mortality in patients with heart failure and ischemic heart disease. In addition, these agents have been used in patients with diabetic nephropathy to control pro...

Oct 2nd, 2020 - Hyperkalemia (HK) is a serious medical condition that can cause potentially fatal cardiac arrhythmias. Patients with heart failure (HF) are at risk of HK due to underlying chronic kidney disease and use of guideline-recommended renin-angiotensin-a...

Sep 30th, 2020 - Tumor lysis syndrome (TLS) is an oncologic emergency due to a rapid break down of malignant cells usually induced by cytotoxic therapy, with hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and serious clinical consequences such as ac...

Dec 17th, 2019 - Suboptimal dosing of renin-angiotensin-aldosterone system (RAAS) inhibitors to reduce the risk of hyperkalemia could increase the risk of major adverse cardiac events (MACE) and all-cause mortality in patients with chronic kidney disease (CKD) or.

Dec 14th, 2019 - Treatment with sodium zirconium cyclosilicate (SZC) led to lasting improvement of hyperkalemia, according to results from an 11-month open-label extension study of the HARMONIZE randomized clinical trial. SZC selectively binds potassium ions in th.

Nov 21st, 2019 - The hyperkalemia that commonly occurs in patients hospitalized for acute heart failure does not affect outcomes, but it can lead to treatment changes that can in turn raise the risk of mortality. That’s according to an analysis of data from 1,589.

Sep 15th, 2019 - Patiromer (Veltassa) works as an adjunctive therapy enabling persistent spironolactone (Aldactone) use among patients with uncontrolled resistant hypertension and chronic kidney disease (CKD), according to a study in nearly 300 people. Twelve week...

Apr 3rd, 2019 - Applying artificial intelligence to the ECG may make it possible to screen patients with chronic kidney disease (CKD) for hyperkalemia without making them get a blood test, a study showed. Researchers trained a deep learning model to predict serum...